Structure-Guided Design, Synthesis, and Evaluation of Novel 6-Methoxyquinoline-4-carboxamide Derivatives as First-in-Class Nano-Molar B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma

Hao Yin Xiao-Wen Yan Bo Fan Xiang-Ye Kong Cong-Ying Gu Wang Zhou Shi-Ping Xu Zeng-Lin Yin Min Zhang You-Chen Wang Hong-Yan Liu Jun-Li Feng Lei-Xi-Ya-Bu-Lei-Ken-Meng-Ya-Ke-Ma-Li-Ya Ge Jia-Chen Li Tang-Tai Dong Yong Yang Da-Yong Zhang Bei-Ying Dai Meng-Han Zhang

Sep 2026 · Journal of Medicinal Chemistry · 0 citations · 46 references

TL;DR

TMLB-G9 is a promising B3GAT3 inhibitor worthy of further development for HCC therapy and exhibits superior anti-HCC activity to TMLB-C16 in two HCC xenograft models.

Abstract

Beta-1,3-glucuronosyltransferase (B3GAT3) is overexpressed in hepatocellular carcinoma (HCC) and correlates with poor prognosis, serving as a desirable anti-HCC target. Based on our micromolar lead TMLB-C16 (IC50 = 6.22−6.53 μM, KD = 3.96 μM), 60 novel derivatives were designed via systematic structure−activity relationship optimization. The optimized candidate TMLB-G9 is the first nanomolar B3GAT3 inhibitor bearing a 6-methoxyquinoline-4-carboxamide scaffold. It exhibits stronger B3GAT3 binding affinity (KD = 0.72 μM) than both TMLB-C16 and natural substrate UDP-GlcUA (KD = 1.32 μM). TMLB-G9 exhibits potent antiproliferative activity against Huh7 and Hep3B cells (IC50 = 0.31−0.36 μM) and broad-spectrum antitumor efficacy. It suppresses HCC colony formation, migration, and invasion, while inducing G0/G1 arrest and apoptosis. With good in vivo tolerance and safety, TMLB-G9 exhibited superior anti-HCC activity to TMLB-C16 in two HCC xenograft models. In conclusion, TMLB-G9 is a promising B3GAT3 inhibitor worthy of further development for HCC therapy.

DOI Semantic Scholar

View source

Similar papers

Open access Sep 2026

Design, synthesis, structure-activity relationship and in-silico studies of novel pyrazolo[1,5-a]pyrimidine derivatives as selective COX-2 inhibitors with promising anti-inflammatory activity and safety profile.

A novel series of pyrazolo[1,5-a]pyrimidine derivatives was designed using ligand-based pharmacophore modeling, and their structures were confirmed by 1H/13C NMR and LC-MS, establishing 8a and 8i as potent, selective, and structurally stable lead candidates for preclinical COX-2 inhibitor development.

Alaa Omar Mohamed Helmy, A. Taher, Eman Z. El Razaz et al. · Bioorganic chemistry (Print) · 0 citations

Open access Sep 2026

Design, synthesis, molecular docking and anticancer activity of novel N-(4-(chlorodifluoromethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives

Results suggest that the N-(4-(chlorodifluoromethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold is a useful template for designing selective BCR-ABL1-directed anticancer agents, with compound 9c as an encouraging lead for further optimisation and mechanistic studies.

Pradeep B. Bhise, Sandeep B. Bhise, Somnath Dasgupta et al. · RSC Advances · 0 citations

Aug 2026

Design, synthesis, antitumor estimation, and molecular docking of new imidazothiazolediones as potential dual EGFR and IDO1 inhibitors and apoptosis stimulators.

Findings highlight compound 5d as a promising lead candidate for further optimization and cellular mechanistic validation in anti-cancer drug discovery.

M. Sarg, Fatma G. Abdulrahman, Yasmin S. Sheta et al. · Bioorganic & Medicinal Chemi... · 0 citations

Design, Synthesis, Characterization and Evaluation of Anticancer Activity of Substituted-4-(Substitutedphenylhydrazon o)-3,4-Dihydroquinolin-2-(1H)-One

The combined computational and biological data suggest that these hydrazinoquinoline derivatives, especially those with electron-withdrawing substituents, hold promise as lead structures for further development in liver cancer therapy targeting EGFR.

Swezel Negredo, B. Biradar, Soniya Phadte et al. · 0 citations

Open access Sep 2026

Design, synthesis, and molecular modeling of quinoline-linked diphenylpyrazoles as multitarget EGFR, VEGFR-2, and COX-2 inhibitors with anticancer, anti-inflammatory and apoptosis-inducing properties.

A new series of quinoline-diphenylpyrazole hybrids were rationally designed, synthesized, and biologically evaluated as potential EGFR/VEGFR-2/COX-2 inhibitors, supporting the proposed hybrid design strategy.

Abdelrahman Hamdi, Mohamed R. Elnagar, M. Hussein et al. · Bioorganic chemistry (Print) · 0 citations

Open access Sep 2026

Design, Synthesis, In Vitro Biological Evaluation, and In Silico Studies of Novel Imidazo[4,5-b]Pyridine-Acrylonitrile-Based Derivatives as VEGFR-2 Inhibitors Against Breast Cancer and Hepatocellular Carcinoma.

Vascular endothelial growth factor receptor-2 (VEGFR-2) is a vital mediator of angiogenesis. Therefore, VEGFR-2 inhibition is considered a promising therapeutic target to combat cancer. In the present study, a series of 22 imidazo[4,5-b]pyridine-acrylonitrile-based derivatives was designed and synthesized. All compound...

Lamia W. Mohamed, Ahmed A. Saadeldin, Ayman B. Farag · Drug development research (P... · 0 citations